2-[1-[4-Amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one;4-methylbenzenesulfonic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 2-[1-[4-Amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one;4-methylbenzenesulfonic acid
• 英文别名: 2-[1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one;4-methylbenzenesulfonic acid
• 化学式: C38H32F3N5O6S
• 分子量: 743.8
• InChiKey: KYJWUPZPSXZEPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  53
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  168
• 氢给体数：
  2
• 氢受体数：
  13

文献信息

• [EN] SELECTIVE PI3K DELTA INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE PI3K DELTA
  申请人：RHIZEN PHARMACEUTICALS SA

  公开号：WO2014006572A1

  公开（公告）日：2014-01-09

  The present invention relates to selective inhibitors of PI3K delta protein kinases having a lH-pyrazolo[3,4-d]pyrimidine ring system, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

  本发明涉及具有lH-吡唑并[3,4-d]嘧啶环系统的PI3K δ蛋白激酶的选择性抑制剂，其制备方法，含有它们的药物组合物以及使用它们治疗和/或预防激酶介导的疾病或紊乱的方法。
• NOVEL SELECTIVE PI3K DELTA INHIBITORS
  申请人：Rhizen Pharmaceuticals SA

  公开号：US20150361083A1

  公开（公告）日：2015-12-17

  The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

  本发明涉及PI3K delta蛋白激酶的选择性抑制剂，其制备方法，包含它们的药物组成物以及使用它们治疗和/或预防激酶介导的疾病或障碍的方法。
• TRIPLE COMBINATION TO TREAT B-CELL MALIGNANCIES
  申请人：TG Therapeutics, Inc.

  公开号：US20220143026A1

  公开（公告）日：2022-05-12

  Methods for treating B-cell malignancies are provided comprising administering a triple combination of agents, comprising: (i) a PI3K-delta selective inhibitor (e.g., umbralisib); (ii) an anti-CD20 antibody (e.g., ublituximab); and (iii) the Bruton's tyrosine kinase (BTK) inhibitor TG-1701. Kits for carrying out the claimed methods are also provided.

  提供了治疗B细胞恶性肿瘤的方法，包括给予三种药物的三重组合治疗，其中包括：(i) PI3K-δ选择性抑制剂(例如，umbralisib)；(ii) 抗CD20抗体(例如，ublituximab)；和(iii) 布鲁顿酪氨酸激酶(BTK)抑制剂TG-1701。还提供了用于执行所述方法的试剂盒。
• COMPOUNDS FOR THE TREATMENT OF COVID-19
  申请人：Dompe' Farmaceutici S.P.A.

  公开号：EP3875078A1

  公开（公告）日：2021-09-08

  The present invention relates to compounds that are able to inhibt 3CL protease of COVID-19 virus, SARS-Cov-2

  本发明涉及能够抑制 COVID-19 病毒、SARS-Cov-2 病毒的 3CL 蛋白酶的化合物。
• Selective PI3K delta inhibitors
  申请人：Rhizen Pharmaceuticals SA

  公开号：US10072013B2

  公开（公告）日：2018-09-11

  The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.

  本发明涉及 PI3K δ 蛋白激酶的选择性抑制剂、制备方法、含有这些抑制剂的药物组合物以及用它们治疗和/或预防激酶介导的疾病或紊乱的方法。